Effect of atmospheric gas plasmas on cancer cell signaling

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1517-1528

  Ishaq, Musarat ^a   Evans, Margaret ^a   Ostrikov, Kostya ^a  

^a CSIRO   (Australia)

Author keywords

atmospheric gas plasmas; cancer; cellular signaling; reactive oxygen species

Indexed keywords

ARGON; HELIUM; MITOGEN ACTIVATED PROTEIN KINASE 14; OXYGEN; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ATMOSPHERIC GAS PLASMA; BIOSAFETY; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL ADHESION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL INTERACTION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DNA DAMAGE; ENZYME ACTIVATION; GLYCOLYSIS; HUMAN; METABOLIC BALANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ATMOSPHERIC GAS PLASMAS; CANCER; CELLULAR SIGNALING; REACTIVE OXYGEN SPECIES;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; HUMANS; NEOPLASMS; PLASMA GASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84892597124     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28323     Document Type: Review

References (113)

1. Shawver LK, Slamon D, Ullrich A,. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117-23.
2. Kaelin WG,. Choosing anticancer drug targets in the postgenomic era. J Clin Invest 1999; 104: 1503-6.
3. Arndt S, Wacker E, Li YF, et al. Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells. Exp Dermatol 2013; 22: 284-9.
4. Kim CH, Kwon S, Bahn JH, et al. Effects of atmospheric nonthermal plasma on invasion of colorectal cancer cells. Appl Phys Lett 2010; 96: 0243701-3.
5. Kim C-H, Bahn JH, Lee S-H, et al. Induction of cell growth arrest by atmospheric non-thermal plasma in colorectal cancer cells. J Biotechnol 2010; 150: 530-8.
6. Kim GC, Kim GJ, Park SR, et al. Air plasma coupled with antibody-conjugated nanoparticles: a new weapon against cancer. J Phys D Appl Phys 2009; 42: 032005.
7. Keidar M, Walk R, Shashurin A, et al. Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer 2011; 105: 1295-301.
8. Kim GJ, Kim W, Kim KT, et al. DNA damage and mitochondria dysfunction in cell apoptosis induced by nonthermal air plasma. Appl Phys Lett 2010; 96: 021502-3.
9. Kim SJ, Chung TH, Bae SH, et al. Induction of apoptosis in human breast cancer cells by a pulsed atmospheric pressure plasma jet. Appl Phys Lett 2010; 97: 023702-3.
10. Kim W, Woo KC, Kim GC, et al. Nonthermal-plasma-mediated animal cell death. J Phys D Appl Phys 2011; 44: 013001-3.
11. Yan X, Xiong ZL, Zou F, et al. Plasma-induced death of HepG2 cancer cells: intracellular effects of reactive species. Plasma Processes Polym 2012; 9: 59-66.
12. Sladek REJ, Stoffels E, Walraven R, et al. Plasma treatment of dental cavities: a feasibility study. IEEE Trans Plasma Sci 2004; 32: 1540-3.
13. Rossi F, Kylian O, Rauscher H, et al. Low pressure plasma discharges for the sterilization and decontamination of surfaces. New J Phys 2009; 11: 115017.
14. Laroussi M,. Nonthermal decontamination of biological media by atmospheric-pressure plasmas: review, analysis, and prospects. IEEE Trans Plasma Sci 2002; 30: 1409-15.
15. Kieft IE, Kurdi M, Stoffels E,. Reattachment and apoptosis after plasma-needle treatment of cultured cells. IEEE Trans Plasma Sci 2006; 34: 1331-6.
16. Nosenko T, Shimizu T, Morfill GE,. Designing plasmas for chronic wound disinfection. New J Phys 2009; 11: 115013.
17. Balasubramanian M, Sebastian A, Peddinghaus M, et al. Dielectric barrier discharge plasma in coagulation and sterilization. Blood 2006; 108: 89b.
18. Moisan M, Barbeau J, Pelletier J,. Plasma sterilization-methods and mechanisms. Vide 2001; 56: 15-28.
19. Sensenig R, Kalghatgi S, Cerchar E, et al. Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species. Ann Biomed Eng 2011; 39: 674-87.
20. Kalghatgi S, Kelly CM, Cerchar E, et al. Effects of non-thermal plasma on mammalian cells. Plos One 2011; 6: e16270.
21. Vandamme M, Robert E, Lerondel S, et al. ROS implication in a new antitumor strategy based on non-thermal plasma. Int J Cancer 2012; 130: 2185-94.
22. Landino LM, Crews BC, Timmons MD, et al. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 1996; 93: 15069-74.
23. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide-dismutase. Arch Biochem Biophys 1992; 298: 431-7.
24. Yamakura F, Taka H, Fujimura T, et al. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 1998; 273: 14085-9.
25. Mannick JB, Schonhoff C, Papeta N, et al. S-nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 1111-6.
26. Bestwick CS, Adam AL, Puri N, et al. Characterisation of and changes to pro- and anti-oxidant enzyme activities during the hypersensitive reaction in lettuce (Lactuca sativa L.). Plant Sci 2001; 161: 497-506.
27. Rao MV, Hale BA, Ormrod DP,. Amelioration of ozone-induced oxidative damage in wheat plants grown under high-carbon dioxide-role of antioxidant enzyme. Plant Physiol 1995; 109: 421-32.
28. Halliwell B,. Reactive oxygen species in living systems: sources, biochemistry and role in human diseases. Am J Med 1991; 91: 14-22.
29. Caputo F, Vegliante R, Ghibelli L,. Redox modulation of the DNA damage response. Biochem Pharmacol 2012; 84: 1292-306.
30. Celardo I, Pedersen JZ, Traversa E, et al. Pharmacological potential of cerium oxide nanoparticles. Nanoscale 2011; 3: 1411-20.
31. Pervaiz S, Clement MV,. Superoxide anion: oncogenic reactive oxygen species? Int J Biochem Cell B 2007; 39: 1297-304.
32. Kim JY, Wei Y, Li J, et al. 15 Mu m-sized single-cellular-level and cell-manipulatable microplasma jet in cancer therapies. Biosens Bioelectron 2010; 26: 555-9.
33. Magne N, Toillon RA, Bottero V, et al. NF-kappa B modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 2006; 231: 158-68.
34. Graves DB,. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J Phys D Appl Phys 2012; 45: 263001-42.
35. Mikkelsen RB, Wardman P,. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 2003; 22: 5734-54.
36. Rothkamm K, Lobrich M,. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 2003; 100: 5057-62.
37. Pierzchalski P, Krawiec A, Gawelko J, et al. Molecular mechanism of protection against chemically and gamma-radiation induced apoptosis in human colon cancer cells. J Physiol Pharmacol 2008; 59: 191-202.
38. Xu Yan FZ, Shasha Zhao, XinPei Lu, et al. On the mechanism of plasma inducing cell apoptosis. IEEE Trans Plasma Sci 2010; 38: 2451-7.
39. Kong MG, Keidar M, Ostrikov K,. Plasmas meet nanoparticles-where synergies can advance the frontier of medicine. J Phys D Appl Phys 2011; 44: 174018.
40. Stoffels E,. Biomedical applications of electric gas discharges. High Temp Mater P-Us 2002; 6: 191-202.
41. Stoffels E, Sakiyama Y, Graves DB,. Cold atmospheric plasma: charged species and their interactions with cells and tissues. IEEE Trans Plasma Sci 2008; 36: 1441-57.
42. Hu W, Kavanagh JJ,. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003; 4: 721-9.
43. Lopez-Lazaro M,. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 2007; 252: 1-8.
44. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
45. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004; 431: 997-1002.
46. Rosen JM, Jordan CT,. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324: 1670-3.
47. Moncharmont C, Levy A, Gilormini M, et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 2012; 322: 139-47.
48. Borst P,. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012; 2: 120066.
49. Abdullah LN, Chow EK,. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 3.
50. Trachootham D, Alexandre J, Huang P,. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-91.
51. Luo J, Solimini NL, Elledge SJ,. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-37.
52. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-20.
53. Cao J, Schulte J, Knight A, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009; 28: 1505-17.
54. Dang CV, Kim J-W, Gao P, et al. Hypoxia and metabolism-opinion-the interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
55. Dang CV, Le A, Gao P,. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-83.
56. Kapitsinou PP, Haase VH,. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 2008; 15: 650-9.
57. Shackelford DB, Shaw RJ,. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-75.
58. De Nicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-9.
59. Fatima Ladelfa M, Fernanda Toledo M, Eva Laiseca J, et al. Interaction of p53 with Tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxid Redox Sign 2011; 15: 1749-61.
60. Li B, Gordon GM, Du CH, et al. Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell 2010; 17: 469-80.
61. Vousden KH, Ryan KM,. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
62. Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLos One 2009; 4: e5137.
63. Kim RH, Peters M, Jang YJ, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 263-73.
64. Lee SR, Yang KS, Kwon J, et al. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 2002; 277: 20336-42.
65. Terada LS,. Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 2006; 174: 615-23.
66. Klatt P, Lamas S,. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000; 267: 4928-44.
67. Spadaro D, Yun BW, Spoel SH, et al. The redox switch: dynamic regulation of protein function by cysteine modifications. Physiol Plantarum 2010; 138: 360-71.
68. Velu CS, Niture SK, Doneanu CE, et al. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 2007; 46: 7765-80.
69. Hancock JT, Desikan R, Neill SJ,. Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans 2001; 29: 345-50.
70. Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999; 401: 79-82.
71. Woo RA, Poon RYC,. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Gene Dev 2004; 18: 1317-30.
72. Toyokuni S, Okamoto K, Yodoi J, et al. Persistent oxidative stress in cancer. FEBS Lett 1995; 358: 1-3.
73. Ames BN,. Dietry carcinogens and anticarcinogens-oxygen radicals and degenrative diseases. Science 1983; 221: 1256-64.
74. Tobiume K, Matsuzawa A, Takahashi T, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001; 2: 222-8.
75. Li SP, Junttila MR, Han JH, et al. p38 mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase. Cancer Res 2003; 63: 3473-7.
76. Elenitoba-Johnson KSJ, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogenactivated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259-64.
77. Lavoie JN, Lallemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44(MAPK) and negatively by the p38/HOG(MAPK) pathway. J Biol Chem 1996; 271: 20608-16.
78. Manke IA, Nguyen A, Lim D, et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G(2)/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17: 37-48.
79. Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210-15.
80. Bulavin DV, Fornace AJ,. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95-118.
81. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Gene Dev 1999; 13: 76-86.
82. Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-45.
83. Nguyen T, Nioi P, Pickett CB,. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-5.
84. Venugopal R, Jaiswal AK,. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998; 17: 3145-56.
85. Hayes JD, McMahon M,. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34: 176-88.
86. Keum Y-S, Yu S, Chang PP-J, et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 2006; 66: 8804-13.
87. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007; 447: 799-816.
88. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-70.
89. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-7.
90. Gorgoulis VG, Vassiliou LVF, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-13.
91. Meek DW,. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9: 714-23.
92. Bateman RL, Rauh D, Tavshanjian B, et al. Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. J Biol Chem 2008; 283: 35756-62.
93. Ralat LA, Manevich Y, Fisher AB, et al. Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry 2006; 45: 360-72.
94. Wang T, Arifoglu P, Ronai Z, et al. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001; 276: 20999-1003.
95. Tournier C, Dong C, Turner TK, et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Gene Dev 2001; 15: 1419-26.
96. Cancer multidrug resistance (Reprinted from Nature Biotechnology, vol 17, pg 94-95, 1999). Nat Biotechnol 2000; 18: It18-20.
97. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Gene Dev 2001; 15: 1311-33.
98. Russo T, Zambrano N, Esposito F, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995; 270: 29386-91.
99. Maehama T, Dixon JE,. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999; 9: 125-28.
100. Brockhoff G, Heckel B, Schmidt-Bruecken E, et al. Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40: 488-507.
101. Cariou S, Donovan JCH, Flanagan WM, et al. Down-regulation of p21(WAF1/CIP1) or p27(Kip1) abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 9042-6.
102. Musgrove EA, Sutherland RL,. Cell-cycle control by steroid-hormones. Seminars Cancer Biol 1994; 5: 381-9.
103. Ihara A, Wada K, Yoneda M, et al. Blockade of leukotriene B-4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007; 103: 24-32.
104. Tong WG, Ding XZ, Hennig R, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002; 8: 3232-42.
105. Tong WG, Ding XZ, Talamonti MS, et al. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 2005; 335: 949-56.
106. Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B-4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-31.
107. Yoo MH, Song HW, Woo CH, et al. Role of the BLT2, a leukotriene B-4 receptor, in Ras transformation. Oncogene 2004; 23: 9259-68.
108. Funk CD,. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
109. Peters-Golden M, Henderson WR, Jr., Mechanisms of disease: leukotrienes. N Engl J Med 2007; 357: 1841-54.
110. Rocconi RP, Kirby TO, Seitz RS, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008; 15: 321-6.
111. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
112. Mokbel K, Hassanally D,. From HER2 to herceptin. Curr Med Res Opin 2001; 17: 51-9.
113. Ostrikov K, Neyts E.C, Meyyappan M., Plasama nanoscience: from nano-solids in plasmas to nano-plasmas in solids. Advances in Physic 2013; 62: 113-224.